In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...